To embed, copy and paste the code into your website or blog:
Earlier this month, Eric Sagonowsky reviewed the top ten drugs in the U.S. (in terms of sales) losing patent exclusivity in an article published by
These drugs are Lucentis (Genentech/Roche), Bystolic (AbbVie/Allergan), Vascepa (Amarin), Nothera (Lundbeck), Narcan (Emergent Biosolutions), Brovana (Sunovion), Sutent (Pfizer), Saphris (AbbVie/Allergan), Amitiza (Mallinckrodt), and Feraheme (Amag Pharma). The nature of these losses and consequences thereof can be seen from the article, synopsized here.
Lucentis (ranibizumab), Roche s drug for macular degeneration, is a humanized mouse monoclonal antibody fragment specific for vascular endothelial growth factor A. It is related to Roche s Avastin (bevacizumab) product, having been modified for injection into the vitreous humor of the eye for the treatment of wet age-related forms of the disease (AMD).